Tucson, along with many other U.S. cities, is experiencing a disturbing increase in opiate addiction. This has become a nationwide epidemic with opiate overdose becoming a leading cause of death for several age groups in various regions of the country. Opioid abuse has been on the increase for over a decade due in large part to the excessive prescribing of opioid pain medications. Tucson offers a selection of qualified doctors approved to treat opiate withdrawal symptoms with suboxone. Suboxone is widely regarded as a beneficial medical intervention for eliminating problematic withdrawal. Buprenorphine is the active ingredient in suboxone that binds to the brain’s opiate receptor sites for an extended span of time consequently eliminating withdrawal while not producing a drug high in suboxone tolerant patients. If you are a local doctor aiming to treat Tucson area residents, you may purchase a featured listing at the top of this page insuring that your medical services will be found by prospective patients searching our website for professional assistance.
Naltrexone is an opioid treatment medication that works very differently than either methadone or buprenorphine.
Naltrexone functions as an opioid blocker that interferes with the euphoric effects of opiates. Unlike methadone, naltrexone does not eliminate opioid withdrawal. So it is typically only begun following a successful period of opioid detoxification.
Naltrexone is taken as a pill or as a time-released injectable. It blocks the feeling of getting high thus deterring a person from continuing in active drug use with opioids. If there’s no pay off for using, why do it?
Some individuals who don’t necessarily require methadone or buprenorphine can effectively utilize naltrexone as a component of their recovery program. Vivitrol is the time-released, branded version of naltrexone that is taken once monthly as an injection. With Vivitrol, the naltrexone remains active in the bloodstream for 30 days and blocks the effects of heroin or other opiate use. This reinforces one’s focus on recovery choices and can reduce opioid cravings.
Patients receiving naltrexone may develop a lowered tolerance to opioids over time, and should remain aware of the risk of opioid overdose should they relapse. The medication is also used in the treatment of alcohol dependency and has been shown to reduce the euphoric effects of alcohol consumption.
Naltrexone is not to be confused with Naloxone. Naloxone is the opioid overdose reversal medication that has recently been in the news for saving thousands of lives across the country.
The national budget proposal for the 2019 fiscal year includes a request for $13 billion in funding for opioid treatment and related services. This linked Newsweek article states that $3 billion would be allocated in 2018 and another $10 billion in 2019.
Many opioid treatment programs across the country are currently able to add patient slots when additional funding is made available. The opioid crisis has flooded many clinics that are already at maximum census due to limited State and Medicaid funding.
A number of private pay clinics have opened in recent years as the need for medication-assisted treatment increased. If a substantial allocation of government funds becomes available, opioid treatment services will finally come into sharp national focus as scores of people finally obtain the help they need to stabilize and to recover.
In treating opioid addiction, research has shown that traditional abstinence-based programs which do not utilize medication assistance have a failure rate of 90%. Medication-assistance is a critical factor in helping opioid addicted people move into sustained recovery. The proposed $13 billion earmarked for opioid treatment services can make a huge difference all across the U.S. Methadone or buprenorphine (suboxone) coupled with counseling and drug testing comprise the gold standard of care in treating opioid addiction.
There is a great article in the Bismarck Tribune about the expansion of methadone services in Fargo, North Dakota. Fargo, like most other areas of the country, was impacted in recent years by numerous opioid-related overdose deaths.
The article reports that Cass County had 31 overdose deaths in 2016, but that number was reduced to 15 in 2017, due in part to the increased availability of naloxone (the medication that reverses opioid overdose).
While local ambulance calls have decreased in relation to opioid overdoses, the problem of opioid addiction remains a widespread and primary concern in the community.
The Tribune story reveals that more local residents are now enrolled in opioid treatment and are receiving the life-saving medication, methadone. Treatment that combines medication-assistance and counseling is the industry standard in quality care for those addicted to opioids.
The new Fargo-based clinic is reported to have 164 active patients currently enrolled in the methadone program. The clinic director, Mark Schaefer, is quoted as saying that while enrollment has been rapid, there remain many people in the local area with untreated opioid addiction.
The availability of treatment is making a difference. And medications like methadone, buprenorphine, and naloxone are providing a much needed solution to America’s opioid crisis.
The nation’s opioid epidemic has reached fever pitch and is now being spotlighted by all levels of local and national media. This is obviously good news.
At the center of this discussion is what can be done to reduce opioid fatalities, and to provide addicted people a real opportunity to regain control over their lives. This discussion inevitably leads to examining the benefit of medication-assisted treatment.
Methadone and buprenorphine are the two leading alternatives for helping patients deal with the perpetual withdrawal sickness that comes from a physiological dependency on opioids. Naloxone is a medication used to reverse opioid overdose.
In recent congressional testimony to members of Congress, Scott Gottlieb (Commissioner of the FDA) specifically heralded the life-saving benefits of methadone and similar medications.
His testimony included comments on the wealth of information behind the effectiveness of medication-assisted treatment. It is vitally important that legislative decision-makers obtain a clear understanding about what works and what does not in regard to coping successfully with this opioid crisis.
Time is of the essence because the present overdose fatality rate in the United States is over 64,000 per year. This number is beyond alarming. Here is an article that points to a possible positive shift in communities’ openness to having local opioid treatment nearby. Hopefully, this becomes a trend.